No Increased Risk of Fatal CV Events for Breast Cancer Patients on Newer Hormone Therapy

Excerpt:

“In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke.

“While women taking aromatose inhibitors did not have an increased risk of death from heart attacks or stroke, the study, published today in JAMA Oncology, found that those who only used aromatase inhibitors or used the drugs after tamoxifen treatment had a 26 to 29 percent higher risk of less serious cardiovascular events, such as abnormal heart beat and pericarditis (a swelling and irritation of the thin membrane surrounding the heart), compared with those who only used tamoxifen.”

Go to full article.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.


New Recommendations for Treating Blood Clots in Cancer Patients

People with cancer are more likely to get blood clots in their veins, which can cause strokes, heart attacks, and other life-threatening conditions. To update the guidelines for preventing and treating blood clots in cancer patients, researchers reviewed 42 existing studies. Their new recommendations include:

  • using low–molecular weight heparin, which is injected;
  • not using new oral anticoagulants;
  • regularly assessing the risk of blood clots;
  • not treating outpatients routinely; and
  • treating patients with cancer throughout hospitalization in most cases, as well as before and after major cancer surgery.

New Recommendations for Treating Blood Clots in Cancer Patients

People with cancer are more likely to get blood clots in their veins, which can cause strokes, heart attacks, and other life-threatening conditions. To update the guidelines for preventing and treating blood clots in cancer patients, researchers reviewed 42 existing studies. Their new recommendations include:

  • using low–molecular weight heparin, which is injected;
  • not using new oral anticoagulants;
  • regularly assessing the risk of blood clots;
  • not treating outpatients routinely; and
  • treating patients with cancer throughout hospitalization in most cases, as well as before and after major cancer surgery.

New Recommendations for Treating Blood Clots in Cancer Patients

People with cancer are more likely to get blood clots in their veins, which can cause strokes, heart attacks, and other life-threatening conditions. To update the guidelines for preventing and treating blood clots in cancer patients, researchers reviewed 42 existing studies. Their new recommendations include:

  • Using low–molecular weight heparin, which is injected;
  • Not using new oral anticoagulants;
  • Regularly assessing the risk of blood clots;
  • Not treating outpatients routinely; and
  • Treating patients with cancer throughout hospitalization in most cases, as well as before and after major cancer surgery.